
News|Articles|April 30, 2025
Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.
Advertisement
Advertisement
Vaccines are a major topic of interest in the world of cancer care, offering the promise of an effective treatment option in traditionally hard-to-manage tumor types that can potentially be personalized for individual patients. In order to further elucidate the current role of vaccines in the therapeutic paradigm of multiple tumor types and learn more about promising vaccines in development, OncLive® interviewed several investigators to gain their perspective on these exciting agents.
Related to this article

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A Mayo Clinic study found that a new immunotherapy helped patients with aggressive bladder cancer keep their bladder instead of having it removed.

Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.

Phase 3 BOND-003 cohort C findings showed a 75.5% CR rate and durable bladder preservation in high-risk, BCG-unresponsive NMIBC.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Advertisement
Advertisement

